se-results surveillance of TALYMUS ophthalmic suspension 0.1% (tacrolimus) in severe allergic keratoconjunctivitis.
Not Applicable
- Conditions
- Severe allergic keratoconjunctivitis
- Registration Number
- JPRN-UMIN000008640
- Lead Sponsor
- Senju Pharmaceutical Co., Ltd
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 1000
Inclusion Criteria
Not provided
Exclusion Criteria
Subjects are ineligible to participate in this surveillance, if they: 1. Have a known hypersensitivity to tacrolimus hydrate or to any component of this drug 2. Are suffering from infectious eye disease 3. Are pregnant or may possibly be pregnant
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method